REDWOOD CITY, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced that Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer, will speak at two upcoming investor conferences being held in New York, NY.
BIO CEO and Investor Conference, February 13-14, 2017
- On Tuesday, February 14, 2017, Mr. Hastings will present a corporate update at 2:30 pm EST.
2017 Leerink Global Healthcare Conference, February 15-16, 2017
- On Thursday, February 16, 2017 at 2:00 pm EST, Mr. Hastings, along with John Lewicki, Ph.D, Executive Vice President, Research and Development, will participate in a fireside chat to discuss recent corporate developments.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, recurrence and metastases. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc, as well as continuing to pursue new drug discovery research efforts. For further information about OncoMed Pharmaceuticals, please see
Contact: OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications email@example.com (650) 995-8373